Qarziba, the first drug to be licensed, evaluated and negotiated, is reviewed by the Drug Review Committee
Qarziba (dinutuximab), first drug to be approved, evaluated and negotiated, to be reviewed by Pharmaceutical Benefits Review Committee [Daily Pharma] […]